Proteomic indicators of metabolic health in diabetes and social deprivation
Background
- Understanding the health impacts of socioeconomic deprivation (SED) and its interaction with type 2 diabetes is important for patient care and effective public health initiatives.
- Large-scale proteomic profiling using aptamer-based technology to measure 7,000 proteins has facilitated the development of blood-based proteomic signatures for 11 cardiometabolic SomaSignal® Tests (SST)
- We applied 11 SSTs to the Psychological, Social, and Biological Determinants of Ill Health (PsoBid) cohort to
characterize the association between cardiometabolic health and social deprivation and diabetes.
Methods
- PsoBid is a cross-sectional study that recruited participants from socioeconomically deprived and affluent areas of Glasgow, Scotland, to identify relevant health disparities.1
- The cohort has similar age ranges and equal proportions of male and female in the affluent and deprived group.
- We used generalized linear model regression analyses to compare means between SSTs (standardized to z-scores) and socioeconomic status and prevalent diabetes and to test for interactions.
Conclusions
- These results demonstrate that participants with diabetes and SED have proteomic phenotypes consistent with worsened cardiometabolic health compared to participants without diabetes or SED.
- SED is associated with worse predicted cardiovascular risk in patients with diabetes.
- While the number of participants with diabetes was small (n = 27, 5.3%), we were able to identify differences in proteomic phenotypes compared to participants without diabetes.
- Proteomics may be useful in identifying and monitoring the health effects of diabetes and SED or the impact of relevant interventions.
Authors
Missy Simpson1
Paul Welsh2
Chris Packard2
Rachel Ostroff1
Stephen Williams1
Naveed Sattar2
1SomaLogic Operating Co., Inc., Boulder, CO, USA
2School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland
Learn more by downloading this poster now
More posters
PosterOptimizing biomarker discovery with focus on low coefficient of variation in large-scale proteomics
Coefficients of variation (CV) describe innate technical variation in high throughput molecular measurement platforms and are a standard metric for characterizing and monitoring assay precision. Median CVs range from ~4.5% to 18.0% for immunoassay technology, 1 up to >30% for mass spectrometry,2 ~5% for the SomaScan® Assay, and ~10% for the Olink Explore Assay (Figure 1). Large CVs can cause technical variability to overwhelm biological signal.
PosterA proteomic predictor of conversion from mild cognitive impairment to dementia with potential utility in enhancing productivity of emerging clinical trials
A significant proportion of individuals with mild cognitive impairment (MCI) develop dementia, with annual conversion rates exceeding 10%. Earlier dementia diagnosis and intervention can improve outcomes, and new disease-modifying drugs are being repositioned for the preclinical stages of illness.
PosterQuantitative immunology protein panel built on the SomaScan Assay platform
The SomaScan® assay is a highly multiplexed proteomic assay that uses SOMAmer® reagents to detect proteins in various biological samples. The latest version of the SomaScan assay allows researchers to measure over 11,000 proteins in human blood. The SomaScan assay is designed to provide protein epitope abundance measurements by reporting relative SOMAmer reagent abundance quantified using DNA microarrays.